Recipharm further expands product development capabilities with new pilot scale development

Complements existing product development and manufacturing capabilities in oral solid, sterile fill & finish and biologics

Recipharm, a leading global contract development and manufacturing organisation (CDMO), announces the opening of its new Pilot Scale Development Centre in Germany. Following the announcement of the investment last year, the new equipment is now fully operational, enhancing Recipharm’s product development (PD) capabilities and reinforcing its commitment to delivering high-quality pharmaceutical solutions.

The new Pilot Scale Development Centre complements Recipharm’s existing product development capabilities, offering customers the assurance of a seamless transition from PD to commercial manufacturing. With state-of-the-art equipment now up and running, Recipharm is equipped to develop and manufacture GMP pilot scale blends, granules, tablets and hard capsules, including both single and dual filling formats. These new capabilities expand upon the company’s expertise in dry granulation, wet granulation and related tools for material characterisation and material science.

The following pilot-scale oral solid dose (OSD) capabilities are now operational:

• Three GMP pilot scale rooms, designed to support development and small-scale manufacturing;
• Compactor, enabling high-quality powder processing;
• Pilot scale hard capsule filler, with dual filling capabilities;
• Tablet press, allowing advanced tableting solutions;
• Compression and compaction simulator, supporting the development of robust formulations;
• Additional equipment for physical characterisation, enhancing analytical capabilities within the ReciPredict ‘Value by Design’ Platform.

This strategic investment addresses the growing industry demand for GMP pilot scale capabilities in product development, technology transfers and commercial small-scale manufacturing. The new facilities empower Recipharm to expedite development timelines for clinical supply, technology transfers, small-batch manufacturing and life cycle management processes.

The expansion of pilot-scale capabilities for oral solid dosage forms complements Recipharm’s broader product development offerings. This includes API development and clinical scale API synthesis, sterile fill & finish solutions, such as pilot scale liquid formulation in vials, in blow-fill seal and in prefilled syringes, as well as laboratories in Bengaluru, India. By integrating these capabilities, Recipharm continues to position itself as a trusted partner for customers, providing end-to-end support from product development through to full-scale commercial manufacturing.

Dr. Uwe Hanenberg, Head of Product Development at Recipharm, commented: “With the addition of these new product development and pilot scale capabilities, alongside our ReciPredict Platform, we can now offer an even faster, cost-efficient and fully integrated solution for oral solids from clinical development to commercialisation.”

Recipharm remains committed to continuous investment in product development capabilities. Looking ahead, the company is set to announce the launch of a Parenteral Development Centre in Bengaluru, India, focusing on sterile liquid formulations, which is scheduled to go live in July 2025.

With these developments, Recipharm continues to reinforce its position as a global leader in pharmaceutical development and manufacturing, offering customers innovative solutions and reliable, high-quality services across multiple markets.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its ReciBioPharm division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm, please visit www.recipharm.com and www.recibiopharm.com

Media contact:
Guenaelle Holloway, Head of communications
[email protected]
+44 7730 303 708